CD8A and neoplasm: The rationale for investigating ibrutinib plus nab-paclitaxel and gemcitabine stems from preclinical evidence whereby the combination of these drugs was shown to reduce tumor growth and to increase effector CD8+ T cells activity in an orthotopic model of PDAC (65).